Clinical trials: Fulvestrant, completed
FGFR Inhibition, Pharmacokinetics, Biomarkers, ER+ Breast Cancer
Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
The purpose of this study is to assess the safety and effectiveness of AZD4547 in combination with fulvestrant vs. fulvestrant alone in ER+ breast cancer patients with FGFR1 polysomy (FISH4/5) or gene amplification (FISH 6)
- Trial name
- GLOW (NCT01202591)
- Testing
- AZD4547, Exemestane, Fulvestrant
- Where
- 21 sites in Belgium, Czechia and 6 more
- Volunteers
- 127 people
- Sponsor
- AstraZeneca
Breast Cancer
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of…
- Trial name
- NCT04460911
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- Pfizer
Puberty, Precocious, McCune-Albright Syndrome
Faslodex in McCune-Albright Syndrome
The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (PPP) (early puberty) in girls with…
- Trial name
- FMAS (NCT00278915)
- Testing
- Fulvestrant
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer
Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
This randomized phase II trial is studying how well giving gefitinib together with anastrozole works compared to giving gefitinib together with fulvestrant in treating postmenopausal women with recurrent or metastatic breast…
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00057941
- Testing
- anastrozole, gefitinib, fulvestrant
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Breast Cancer
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or…
- Trial name
- ALPINIST (NCT05631795)
- Testing
- Alpelisib, Fulvestrant
- Where
- 12 sites in India
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Breast Cancer, Hormone Receptor Positive
A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer
This phase II trial studies the side effects of palbociclib when given together with fulvestrant or tamoxifen citrate in treating patients with hormone receptor positive breast cancer that has spread from where it started to…
- Trial name
- NCT02384239
- Testing
- Palbociclib, Tamoxifen, Fulvestrant
- Where
- 9 sites in United States
- Volunteers
- 70 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
The primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help participants who have breast cancer and make the tumor smaller or disappear and for…
- Trial name
- NCT00451555
- Testing
- enzastaurin, fulvestrant
- Where
- 21 sites in France, Germany and 3 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
The purpose of a phase Ib study is to find out the best or maximum tolerated dose of a medication or combination of medications.
- Trial name
- NCT03344536
- Testing
- Fulvestrant, Debio 1347
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hormone Receptor Positive HER-2 Negative Breast Cancer
Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer
This study aims to evaluate the hematological safety of palbociclib with letrozole and fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.
- Trial name
- PALINA (NCT02692755)
- Testing
- Palbociclib + Letrozole or Fulvestrant
- Where
- 6 sites in United States
- Volunteers
- 35 people
- Sponsor
- Georgetown University
Breast Cancer
Fulvestrant and Bevacizumab in Treating Patients With Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00423917
- Testing
- bevacizumab, fulvestrant
- Where
- 205 sites in United States
- Volunteers
- 36 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Advanced Solid Malignancies
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant…
- Trial name
- NCT03363893
- Testing
- CT7001, Fulvestrant
- Where
- 23 sites in United States, United Kingdom
- Volunteers
- 124 people
- Sponsor
- Carrick Therapeutics Limited
Breast Cancer
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using drugs such as anastrozole and fulvestrant may fight breast cancer by blocking the use of estrogen.
- Trial name
- NCT00075764
- Testing
- anastrozole, fulvestrant
- Where
- 426 sites in United States, Canada
- Volunteers
- 695 people
- Sponsor
- SWOG Cancer Research Network
Estrogen Receptor Status, HER2/Neu Negative
Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body.
- Conditions
- Estrogen Receptor Status, HER2/Neu Negative, Invasive Breast Carcinoma, Postmenopausal
- Trial name
- NCT02860000
- Testing
- Alisertib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 96 people
- Sponsor
- Mayo Clinic
Metastatic Breast Cancer
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
This international, multicenter, prospective single arm Phase II biomarker discovery clinical trial with the primary objective of assessing the association of PFS with gene mutations, gene copy number aberrations and gene…
- Trial name
- PYTHIA (NCT02536742)
- Testing
- Palbociclib, Fulvestrant
- Where
- 19 sites in Belgium, Italy and 1 more
- Volunteers
- 124 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Ganetespib is a drug that may stop cancer cells from growing. This drug has been used in other research studies and laboratory experiments.
- Trial name
- NCT01560416
- Testing
- Fulvestrant, Ganetespib
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive…
- Trial name
- FACT (NCT00256698)
- Testing
- Fulvestrant, Anastrozole
- Where
- 85 sites in Canada, Costa Rica and 10 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Advanced Breast Cancer
AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal…
- Trial name
- NCT00454805
- Testing
- AZD2171, Fulvestrant
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 75 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer, Breast Carcinoma
Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
This is a randomized trial for patients with metastatic hormone receptor (HR)-positive human epidermal growth factor receptor 2 (HER2)-negative breast cancer who have progressed on an aromatase inhibitor plus a CDK4/6 inhibitor…
- Trial name
- MAINTAIN (NCT02632045)
- Testing
- LEE-011, Fulvestrant
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Melissa K Accordino
Breast Cancer
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of enzalutamide alone and in combination with anastrozole, or exemestane, or fulvestrant in patients with incurable breast cancer.
- Trial name
- NCT01597193
- Testing
- enzalutamide, anastrozole, exemestane
- Where
- 17 sites in United States
- Volunteers
- 101 people
- Sponsor
- Pfizer
Breast Cancer, HER2-negative Breast Cancer
Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer
The purpose of this study is to learn if adding a new drug that is targeted at a specific genetic change found in some breast tumors pre-operatively will slow the growth of the tumor more than standard anti-hormone therapy used…
- Conditions
- Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer
- Trial name
- NCT05101564
- Testing
- Alpelisib, Tamoxifen, Zotatifin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jennifer Lee Caswell-Jin